摘要
目的观察雷珠单抗玻璃体内注射及广泛视网膜光凝(panretinal photocoagulation,PRP)治疗新生血管性青光眼的效果。方法回顾性分析2015年1月至2018年2月在巴彦淖尔市残联眼科医院就诊的新生血管性青光眼20例(20眼)的临床资料。所有患者均采用雷珠单抗(lucentis)0.5 mg/0.05 ml玻璃体内注射,1周后行PRP。结果治疗后随诊3个月,患者眼压为(19.45±8.54)mmHg,较治疗前的(41.80±9.84)mmHg(1 mmHg=0.133 kPa)明显降低(P=0.000);治疗后视力明显改善(P=0.000)。虹膜和前房角的新生血管基本消退。未出现严重并发症或不良反应。结论雷珠单抗玻璃体内注射联合广泛视网膜光凝治疗新生血管性青光眼能显著降低眼压,改善视力,无明显不良反应。
Objective To observe the efficacy of intravitreal ranibizumab injection with panretinal photocoagulation for the treatment of neovascular glaucoma.Methods Total of 20 eyes of 20 cases with neovascular glaucoma in Bayannur Federation of Disabled People’s Eye Hospital from Jan.2015 to Feb.2018 were analyzed retrospectively.All cases were treated with intravitreal ranibizumb injection(0.5 mg/0.05 ml)and panretinal photocoagulation at 1 week after injection.Results The IOP was(19.45±8.54)mmHg(1mmHg=0.133 kPa)at 3 months after treatment,which was significantly lower than that before treatment(41.80±9.84)mmHg(P=0.000).The visual acuity was improved significantly(P=0.000).The new vessels of iris and anterior chamber angle basically disappeared.There was no serious complication or adverse reactions in all patients.Conclusion Intravitreal ranibizunmb injection combined with panretinal photocoagulation for the treatment of neovascular glaucoma can significantly reduce the IOP and improve visual function of the patients without obvious adverse reactions.
作者
胡永成
张智科
张萍
张旭东
Hu Yongcheng;Zhang Zhike;Zhang Ping;Zhang Xudong(Bayannaoer Federation of Disabled People’s Eye Hospital,Inner Mongolia 015000,China;Department of Ophthalmology,China-Japanese Friendship Hospital,Beijing 100029,China)
出处
《中华眼外伤职业眼病杂志》
2019年第11期853-856,共4页
Chinese Journal of Ocular Trauma and Occupational Eye Disease
作者简介
通信作者:胡永成,Email:527888246@qq.com,电话:0478-2250882。
